Table 2.

Summary of unsolicited TEAEs through 28 days following any vaccination (safety population).

	mRNA-1283				mRNA-1273
n (%)	10 µg (n = 21)	30 µg (n = 22)	100 µg (n = 21)	Placebo + 100 µg (n = 18)	100 µg (n = 22)
All unsolicited TEAEs
All AEs	8 (38.1)	9 (40.9)	9 (42.9)	4 (22.2)	7 (31.8)
SAEs	0	0	0	0	0
Fatal AEs	0	0	0	0	0
MAAEs	3 (14.3)	2 (9.1)	2 (9.5)	2 (11.1)	3 (13.6)
AEs leading to vaccination discontinuation	0	0	0	0	1 (4.5)
AEs leading to study discontinuation	0	0	0	0	0
Severe	0	0	0	0	0
AESIs	0	0	0	0	0
Related unsolicited TEAEs
All AEs	2 (9.5)	4 (18.2)	4 (19.0)	2 (11.1)	4 (18.2)
SAEs	0	0	0	0	0
Fatal AEs	0	0	0	0	0
MAAEs	0	1 (4.5)	1 (4.8)	0	1 (4.5)
AEs leading to vaccination discontinuation	0	0	0	0	1 (4.5)
AEs leading to study discontinuation	0	0	0	0	0
Severe	0	0	0	0	0
AESIs	0	0	0	0	0

A TEAE is any event not present before exposure to study vaccination or any event already present that worsened in intensity or frequency after exposure.

Abbreviations: AE, adverse event; AESI, adverse event of special interest; MAAE, medically attended adverse event; mRNA, messenger RNA; SAE, serious adverse event; TEAE, treatment-emergent adverse event.